Ascendis Pharma (ASND) Reports Q3 Loss of EUR0.30/Share

Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR0.30), versus (EUR0.18) reported last year. Revenue for the quarter came in at EUR2.1 million, versus EUR3.3 million reported last year.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BMO Capital Starts Ascendis Pharma (ASND) at Outperform
• Beike (BEKE) PT Raised to $23 at Morgan Stanley